13F Holdings
中文EN

SNGX SOLIGENIX, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 812796 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-85.8%
TTM net income YoY-34.6%
TTM EPS YoY60.7%
Revenue 3-yr CAGR-47.5%
Net income 3-yr CAGR—

Margins

Gross margin0.0%
Operating margin-7,907.7%
Net margin-6,925.1%
FCF margin—
EBITDA margin—

Returns

ROE-249.0%
ROA-88.1%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets54.1%
Debt / equity0.00x
Current ratio1.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio1.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$119,371$839,359$948,911$824,268
Cost of revenue—$119,371$742,048$550,822$728,640
Gross profit—$0$97,311$398,089$95,628
R&D expense$7.49M$5.22M$3.31M$7.94M$8.19M
SG&A expense$4.36M$4.22M$4.48M$6.69M$5.01M
Operating income-$11.85M-$9.44M-$7.70M-$14.24M-$13.10M
Pretax income-$11.59M-$8.68M-$7.91M-$14.95M-$13.42M
Income tax-$506,615-$409,114-$1.77M-$1.15M-$864,742
Net income-$11.08M-$8.27M-$6.14M-$13.80M-$12.55M
EBITDA————-$13.06M
EPS (basic)-2.14-4.98-12.66-4.81-4.69
EPS (diluted)-2.14-4.98-12.66-4.81-4.69
Weighted avg. shares (diluted)5.19M1.66M484,9952.87M2.68M
Banking
Net interest income————-$862,577
Deposits————$250,000
Balance sheet
Cash & equivalents$7.94M$7.82M$8.45M$13.36M$26.04M
Current assets$8.85M$8.83M$9.51M$13.85M$26.57M
PP&E, net$8,772$6,113$11,927$18,481$22,220
Total assets$9.24M$8.97M$9.80M$14.28M$26.87M
Current liabilities$3.70M$4.85M$6.15M$16.52M$6.29M
Long-term debt—$0$1.01M$0—
Total debt—$0$1.01M$0—
Total liabilities$3.94M$4.85M$7.27M$16.75M$16.15M
Shareholders' equity$5.29M$4.12M$2.52M-$2.47M$10.72M
Net debt—-$7.82M-$7.44M-$13.36M—
Shares outstanding10.09M2.51M648,7612.91M2.86M
Cash flow statement
Operating cash flow-$10.27M-$8.40M-$8.60M-$12.65M-$11.74M
Capital expenditure$5,883————
Free cash flow-$10.27M————
Investing cash flow-$5,883——-$13,073-$11,789
Financing cash flow$10.39M$7.76M$3.66M$76,821$19.06M
Depreciation & amortization————$34,161
Stock-based compensation$587,583$329,815$370,182$333,389$361,559

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.